We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
+4.82%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
AUM
$22.6M
AUM Growth
-$11.3M
Cap. Flow
-$10.8M
Cap. Flow %
-48.04%
Top 10 Hldgs %
100%
Holding
2
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$20M 88.84%
2,697,829
-1,750,000
-39% -$10.8M
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$2.52M 11.16%
2,790,964

Similar funds

TRV GP II's Q3 2021 Portfolio in Review

As of Q3 2021, TRV GP II held 2 positions worth $22.6M, down 33% from $33.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $10.8M in Q3 2021, reducing 1 holding. Its largest reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's biggest Q3 2021 reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $10.8M.
  • TRV GP II's ten largest holdings make up 100% of its $22.6M portfolio in Q3 2021.
  • TRV GP II opened 0 new positions and closed 0 in Q3 2021.
  • TRV GP II's portfolio value fell 33% quarter-over-quarter to $22.6M.

Based on TRV GP II's 13F filing for Q3 2021, filed 5 Nov 2021.